Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 30.35 USD -0.52% Market Closed
Market Cap: 975.4m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one COLL stock under the Base Case scenario is 66.15 USD. Compared to the current market price of 30.35 USD, Collegium Pharmaceutical Inc is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COLL Relative Value
Base Case
66.15 USD
Undervaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
80
vs Industry
60
Median 3Y
1.7
Median 5Y
2
Industry
2.5
Forward
1.3
More Details
22.2
P/E
P/E
Price to Earnings
22.2
vs History
20
vs Industry
33
Median 3Y
12.3
Median 5Y
12.5
Industry
21.2
Forward
3.8
More Details
4.9
P/OCF
P/OCF
Price to OCF
4.9
vs History
58
vs Industry
48
Median 3Y
4.5
Median 5Y
6.3
Industry
16.3
More Details
5.2
P/FCFE
P/FCFE
Price to FCFE
5.2
vs History
42
vs Industry
33
Median 3Y
5.5
Median 5Y
4.5
Industry
23.8
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
41
vs Industry
17
Median 3Y
4.1
Median 5Y
4
Industry
2.1
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
50
vs Industry
43
Median 3Y
2.4
Median 5Y
2.4
Industry
2.6
Forward
2
More Details
4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4
vs History
61
vs Industry
47
Median 3Y
4.1
Median 5Y
4.3
Industry
5.2
More Details
4.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4.8
vs History
58
vs Industry
47
Median 3Y
4.7
Median 5Y
5.6
Industry
12.5
Forward
3.5
More Details
11.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.9
vs History
49
vs Industry
39
Median 3Y
10.1
Median 5Y
11.8
Industry
15.9
Forward
5
More Details
7.8
EV/OCF
EV/OCF
Enterprise Value to OCF
7.8
vs History
44
vs Industry
43
Median 3Y
7.4
Median 5Y
7.7
Industry
14.6
More Details
7.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.9
vs History
12
vs Industry
34
Median 3Y
4.4
Median 5Y
4.4
Industry
17.2
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
73
vs Industry
55
Median 3Y
1.2
Median 5Y
1.3
Industry
1.8
More Details

Multiples Across Competitors

COLL Competitors Multiples
Collegium Pharmaceutical Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
975.2m USD 1.5 22.2 4.8 11.9
US
Eli Lilly and Co
NYSE:LLY
739.9B USD 15.1 66.6 35.8 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.3B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.6 12.9 14.8
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
189.7B CHF 4.5 18.6 10.9 14.6
UK
AstraZeneca PLC
LSE:AZN
158.2B GBP 3.9 27.8 130.6 197
US
Merck & Co Inc
NYSE:MRK
203.6B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
Average P/E: 25.1
22.2
52%
0.4
US
Eli Lilly and Co
NYSE:LLY
66.6
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.6
18%
1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
Average EV/EBITDA: 394.6
4.8
4%
1.2
US
Eli Lilly and Co
NYSE:LLY
35.8
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.9
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
Average EV/EBIT: 1 698.5
11.9
30%
0.4
US
Eli Lilly and Co
NYSE:LLY
39.1
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.6
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
COLL intrinsic value, competitors valuation, and company profile.
DCF Valuation
COLL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
COLL stock valuation using valuation multiples.
Wall Street Estimates
COLL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
COLL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 265,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.